Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
NCT00063895 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2013-01-09
Summary
This phase I/II trial is studying the side effects of erlotinib and to see how well it works in treating patients with metastatic or unresectable non-small cell lung cancer, ovarian cancer, or squamous cell carcinoma (cancer) of the head and neck. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth
Conditions
- Recurrent Non-small Cell Lung Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Recurrent Squamous Cell Carcinoma of the Larynx
- Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Recurrent Squamous Cell Carcinoma of the Nasopharynx
- Recurrent Squamous Cell Carcinoma of the Oropharynx
- Stage III Squamous Cell Carcinoma of the Hypopharynx
- Stage III Squamous Cell Carcinoma of the Larynx
- Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage III Squamous Cell Carcinoma of the Nasopharynx
- Stage III Squamous Cell Carcinoma of the Oropharynx
- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIA Ovarian Epithelial Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IIIB Ovarian Epithelial Cancer
- Stage IIIC Ovarian Epithelial Cancer
- Stage IV Non-small Cell Lung Cancer
- Stage IV Ovarian Epithelial Cancer
- Stage IV Squamous Cell Carcinoma of the Hypopharynx
- Stage IV Squamous Cell Carcinoma of the Nasopharynx
- Stage IVA Squamous Cell Carcinoma of the Larynx
- Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IVA Squamous Cell Carcinoma of the Oropharynx
- Stage IVB Squamous Cell Carcinoma of the Larynx
- Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Stage IVC Squamous Cell Carcinoma of the Larynx
- Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IVC Squamous Cell Carcinoma of the Oropharynx
Interventions
- DRUG
-
erlotinib hydrochloride
Given PO
- OTHER
-
pharmacological study
Correlative studies
- OTHER
-
pharmacogenomic studies
Correlative studies
- OTHER
-
laboratory biomarker analysis
Correlative studies
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Charles Rudin · University of Chicago Comprehensive Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-04-30
- Primary Completion
- 2005-10-31
Countries
- United States
Study Locations
More Related Trials
-
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
NCT00217529 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
NCT02983799 ·Status: COMPLETED ·Phase: PHASE2
-
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00126542 ·Status: COMPLETED ·Phase: PHASE2
-
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
NCT02101788 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
NCT00522301 ·Status: TERMINATED ·Phase: PHASE2
-
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
NCT04566952 ·Status: UNKNOWN ·Phase: PHASE2
-
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
NCT00132067 ·Status: COMPLETED ·Phase: PHASE2
-
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314 ·Status: RECRUITING ·Phase: PHASE3
-
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
NCT03924245 ·Status: TERMINATED ·Phase: PHASE1
-
Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum
NCT00003523 ·Status: COMPLETED ·Phase: PHASE2
-
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
NCT05276973 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
NCT04585958 ·Status: RECRUITING ·Phase: PHASE1
-
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
NCT01684878 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
NCT06394804 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
NCT03695380 ·Status: COMPLETED ·Phase: PHASE1
-
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT01459380 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of SHR-A1811 in Subjects With Ovarian Cancer
NCT06828354 ·Status: RECRUITING ·Phase: PHASE3
-
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
NCT03345784 ·Status: TERMINATED ·Phase: PHASE1
-
Erlotinib Prevention of Oral Cancer (EPOC)
NCT00402779 ·Status: COMPLETED ·Phase: PHASE3
-
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957 ·Status: RECRUITING ·Phase: PHASE1
-
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01074411 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
NCT02558348 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
NCT06840002 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
NCT00006812 ·Status: TERMINATED ·Phase: PHASE2